per Marc - we have the best io/io data in nsclc. Will be interesting to see how the nsclc trial progresses to ph3. Surely Merck need to make a significant upfront payment before we move to ph3, in exchange we could provide exclusivity in nsclc. otherwise if negotiations with merck fail, good chance of a significant raise to try and go it alone - in which case you’d bring in another pd1 drug thats not keytruda as a means for the competition to take a slice of mercks sales in this setting.
Media, page-362
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $435.7M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.5¢ | 28.8¢ | $574.2K | 1.921M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 461775 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |